Well, in spite of A.F. latest tirade, INGN stock has continued to recover on low volume.<g>
bigcharts.marketwatch.com
These are some of his latest comments.He has refrained to compare the p53 biomarker with his important left handed biomarker.<g>
I'm actually looking forward to more tomfoolery from Introgen next month, when the company is expected to release interim results from its never-completed and often-manipulated phase III study of Advexin in head and neck cancer patients.
And of course, there is Europe, where regulators may, or may not, approve Advexin as a compassionate use treatment for patients with Li-Fraumeni syndrome. Of course, there are about a dozen people in the world with that genetic disease, and the regulatory package compiled by Introgen to support its approval claim amounts to data from a single patient. Good luck there, guys.
He says that there are about a dozen people in the world with that genetic disease. Apparently he isn't aware of the statistics from Dana-Farber Cancer Institute, & the Department of Epidemiology at Harvard School of Public Health,which reported on just 200 Li-Fraumeni syndrome family members diagnosed with cancer.<g>
jnci.oxfordjournals.org
My best advice would be to sell all but one share of Introgen. Then, if they still do such things, get your broker to send you an actual Introgen stock certificate.
Put that single share of Introgen in a cheap frame (you'll probably spend more for the frame than the stock is worth) and hang it on the wall next to your computer. Then, the next time you consider making an investment in a bottomless, money-draining biotech outfit, you can look up at the Introgen stock certificate and stop yourself before you lose even more money.
Of course, he didn't give any advise to the shorts, himself probably included,who will have to spend about $14M or $18M to buy back the shares that they have borrowed at the present price level.<g>
And he also didn't mention the $7,549,000 that INGN raised recently on the sale of its shares of Silence Therapeutics, which according to David Nance, provided an attractive return on INGN's investment & also additional cash to deploy on its development programs.INGN's program with Silence to investigate applications of INGN's delivery technologies for RNAi use was not affected by the stock sale.
INGN stock has been up 5.82% at its intraday H at 10:50AM, which isn't a bad return for one day when the average one year CD yield is < 3.5% <g>
It seems that with some news & short covering the stock could double from present levels.<g>
bigcharts.marketwatch.com
Bernard |
